Cabozantinib | List of Frontiers open access articles

Original Research

Published on 19 Apr 2021

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

in Pharmacology of Anti-Cancer Drugs

Hongyan Liu
Shishuo Sun
Gang Wang
Mengmeng Lu
Xiaokang Zhang
Xiaohuan Wei
Xiaoge Gao
Chao Huang
Zhen Li
Junnian Zheng

Frontiers in Oncology

doi 10.3389/fonc.2021.663517

6,741 views
19 citations

Original Research

Published on 08 Dec 2021

A Combination of Cabozantinib and Radiation Does Not Lead to an Improved Growth Control of Tumors in a Preclinical 4T1 Breast Cancer Model

in Radiation Oncology

Norman Reppingen
Alexander Helm
Laura Doleschal
Marco Durante
Claudia Fournier

Frontiers in Oncology

doi 10.3389/fonc.2021.788182

5,590 views
8 citations

Original Research

Published on 20 Oct 2021

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

in Cancer Molecular Targets and Therapeutics

Fabio Scirocchi
Chiara Napoletano
Angelica Pace
Hassan Rahimi Koshkaki
Alessandra Di Filippo
Ilaria Grazia Zizzari
Marianna Nuti
Aurelia Rughetti

Frontiers in Oncology

doi 10.3389/fonc.2021.755433

7,987 views
36 citations

Case Report

Published on 01 Feb 2021

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report

in Genitourinary Oncology

Mehmet A. Bilen
James F. Jiang
Caroline S. Jansen
Jacqueline T. Brown
Lara R. Harik
Aarti Sekhar
Haydn Kissick
Shishir K. Maithel
Omer Kucuk
Bradley Carthon

Frontiers in Oncology

doi 10.3389/fonc.2020.622134

5,988 views
5 citations

Original Research

Published on 03 Mar 2023

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

in Drugs Outcomes Research and Policies

Maciej Niewada
Tomasz Macioch
Magdalena Konarska
Aneta Mela
Adam Goszczyński
Bogusława Przekopińska
Karolina Rajkiewicz
Piotr Wysocki
Maciej Krzakowski

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1063178

8,023 views
8 citations

Original Research

Published on 22 Mar 2021

Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model

in Molecular and Cellular Oncology

Zi-Ning Lei
Qiu-Xu Teng
Pranav Gupta
Wei Zhang
Silpa Narayanan
Dong-Hua Yang
John N. D. Wurpel
Ying-Fang Fan
Zhe-Sheng Chen

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.640957

5,841 views
17 citations

Original Research

Published on 06 Nov 2019

Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)

in Cancer Molecular Targets and Therapeutics

Pei-Wen Yang
Yu-Cheng Liu
Ya-Han Chang
Ching-Ching Lin
Pei-Ming Huang
Kuo-Tai Hua
Jang-Ming Lee
Min-Shu Hsieh

Frontiers in Oncology

doi 10.3389/fonc.2019.01138

7,898 views
18 citations

Brief Research Report

Accepted on 23 Jan 2026

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status

in Head and Neck Cancer

Marcia Brose
Bhumsuk Keam
Jolanta Krajewska
Ana Hoff
Fernanda Vaisman
Chia-Chi Lin
Erika Hitre
Daniel W. Bowles
Bruce Robinson
Steven I. Sherman

Frontiers in Oncology

258 views

Original Research

Published on 13 Dec 2021

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States

in Drugs Outcomes Research and Policies

SiNi Li
JianHe Li
LiuBao Peng
YaMin Li
XiaoMin Wan

Frontiers in Pharmacology

doi 10.3389/fphar.2021.736860

5,090 views
10 citations

Original Research

Published on 30 Jun 2022

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

in Drugs Outcomes Research and Policies

Bo Shi
Wenbiao Ma
Hongshuai Pan
Yang Shi
Huan Zhang
Shenghai Xing

Frontiers in Pharmacology

doi 10.3389/fphar.2022.860615

3,217 views
4 citations

Clinical Trial

Published on 11 Mar 2019

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

in Thoracic Oncology

Karen L. Reckamp
Paul H. Frankel
Nora Ruel
Philip C. Mack
Barbara J. Gitlitz
Tianhong Li
Marianna Koczywas
Shirish M. Gadgeel
Mihaela C. Cristea
Chandra P. Belani

Frontiers in Oncology

doi 10.3389/fonc.2019.00132

8,521 views
40 citations

Original Research

Published on 09 Oct 2025

Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

in Drugs Outcomes Research and Policies

Yan Zhu
Cheng He
Shi-Chao Cao
Hui-Jun Li
Ru-Xue Cai
Zhao-Jun Bai
Tong-Xia Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1556304

3,266 views

Case Report

Published on 27 Nov 2020

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature

in Neuroendocrine Science

Minas P. Economides
Amishi Y. Shah
Camilo Jimenez
Mouhammed A. Habra
Monica Desai
Matthew T. Campbell

Frontiers in Endocrinology

doi 10.3389/fendo.2020.594264

5,830 views
19 citations

Case Report

Published on 28 Aug 2018

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

in Gastrointestinal Cancers

Jingquan Jia
Michael A. Morse
Rebecca J. Nagy
Richard B. Lanman
John H. Strickler

Frontiers in Oncology

doi 10.3389/fonc.2018.00305

4,805 views
17 citations

Systematic Review

Published on 17 Apr 2024

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Jingyang Su
Jialin Zhang
Yuqian Wu
Cui Ni
Yueyue Ding
Zelin Cai
Ming Xu
Mingyang Lai
Jue Wang
Shengyou Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1322473

4,512 views
4 citations

Case Report

Published on 14 Jul 2023

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature

in Genitourinary Oncology

Anezka Zemankova
Hana Studentova
Andrea Kopova
Tomas Tichy
Vladimir Student
Bohuslav Melichar

Frontiers in Oncology

doi 10.3389/fonc.2023.1115901

3,126 views
3 citations

Articles

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity

A Combination of Cabozantinib and Radiation Does Not Lead to an Improved Growth Control of Tumors in a Preclinical 4T1 Breast Cancer Model

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab

Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model

Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature